Epigenetic Reprogramming: The Next Trillion-Dollar Health Frontier
New Limit raised $435M at a $3.1B valuation to develop epigenetic reprogramming therapies targeting alcohol-related liver disease as an FDA-approved entry point. Peter Diamandis says longevity is a hundreds-of-trillions-of-dollars opportunity — and it's finally tractable.
